Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma

Table 1 MDR1, MRP, LRP primers for RT-PCR amplifications

Gene	Quantification method	Sequence	cDNA
MDR1	Forward primer	5- CATTGGTGTGGTGAGTCAGG-3	1523-1542
	Reverse primer	5- CTCTCTCTCCAACCAGGGTG-3	1679-1698
MRP	Forward primer	5- CTACCGAGAGGACCTGGACT-3	4099-4118
	Reverse primer	5- GTCTAGCTTGTCAGGAAGGG-3	4437-4456
LRP	Forward primer	5- TAAGGGCTTCCAGCACCAAC-3	148-167
	Reverse primer	5- GGAGTTCTCGCTTCTCGTCC-3	520-539
β-actin	Forward primer	5- GTGTTTGGCCGAGTCCTCACC-3
	Reverse primer	5- CTCCTGCAAGGAAAAGCTCTG-3

Table 2 Oligonucleotides used for PCR amplifications

Gene	Quantification method	Sequence	cDNA
MDR1	Forward primer	5’- CCCAGGAGCCCATCCTGT-3’	3774-3791
	Revease primer	5’- CCCGGCTGTTGTCTCCATA-3’	3838-3821
	Probe	5’-(FAM)TGACTGCAGCATTGCTGAGAACATTGC(TAMRA)-3’3793-3819
MRP	Forward primer	5’- AAGCGCCTCGAGTCGGT-3’	3617-3633
	Revease primer	5’- TCGAATGACGCTGACCCC-3’	3694-3677
	Probe	5’-(FAM)AGCCGCTCCCCGGTCTATTCCC-(TAMRA)-3’	3635-3656
LRP	Forward primer	5’- TTTCGATGACTTCCATAAGAACTCA-3’	1881-1905
	Reverse primer	5’- TTCCGAGGTCTCAAAGCCAA-3’	1950-1931
	Probe	5’(FAM)-CCCGCATCATTCGCACTGCTGT- (TAMRA)3’	1907-1928
GAPDH	Forward primer	5’- GAAGGTGAAGGTCGGAGTCA-3’
	Revease primer	5’- GAAGATGGTGATGGGA-3’
	Probe	5’-(JOE)CAAGCTTCCCGTTCTCAGCC(TAMRA)-3’

Table 3 Patient characteristics and radionuclide imaging

Group	Cases	Tumor size (cm)	99mTc-MIBI SPECT			Immunohistochemistry			RT-PCR
			L/Ne	L/Nd	L/Nwr (%)	Pgp	MRP	LRP	mdr1	MRP	LRP
I	68	2.5-15	2.09 ± 0.67	1.25 ± 0.42	54.94 ± 10.23	68 (+)	4 (+)	3 (+)	0.38 ± 0.16	0.04 ± 0.02	0.02 ± 0.01
II	10	1.5-7	1.98 ± 0.56	2.78 ± 0.53	3.07 ± 0.57	10 (-)	3 (+)	1 (+)	0	0.06 ± 0.03	0.03